---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-084084"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:31:18.038767+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alaunos reports positive preclinical data for ALN1003; weight loss up to 12.9% in DIO mice

## Summary
- ALN1003 showed dose-dependent body weight loss: -12.9% peak (Day 34) and -10.3% after 48 days vs DIO control (p<0.0001).
- Liver weight reduced 43% (p<0.0001); liver enzymes ALT, AST, ALP significantly decreased in Study 1.
- Highest-dose group lowered glucose to 197 mg/dL (vs 320 control) and total cholesterol to 162 mg/dL (vs 209).
- Cash and equivalents ~$1.9M as of Sept 30, 2025; runway into Q2 2026; additional financing being pursued.
- ALN1003 is an oral non-hormonal small molecule; company planning IND-enabling studies and next-gen compounds.

## SEC filing metadata
- accession: 0001193125-26-084084
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312526084084/0001193125-26-084084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312526084084/tcrt-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-084084
- JSON: https://secwatch.observer/filing/0001193125-26-084084.json
- Plain text: https://secwatch.observer/filing/0001193125-26-084084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.